Consistent with this finding, we further implicate involvement of PI3K/Akt/mTOR signalling in modulating sensitivity to MEK1/2 inhibition in melanoma, which is consistent with previous studies[9,12,45,46]. The gene discussed is MTOR; the disease is melanoma.